NVCR Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

168.93M

+4.75%

-0.393

-35.6%

168.39M

+8.64%

-0.372

+20%

172.28M

+8.49%

-0.358

-0.56%

Estimates Revision

The market is revising Upward the revenue expectations for NovoCure Limited (NVCR) for FY2025, with the revenue forecasts being adjusted by 3.16% over the past three months. During the same period, the stock price has changed by 6.38%.

Revenue Estimates for FY2025

Revise Upward

+3.16%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-12.31%

In Past 3 Month

Stock Price

Go Up

+6.38%

In Past 3 Month

5 Analyst Rating

Wall Street analysts forecast NVCR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NVCR is 28.40 USD with a low forecast of 18.00 USD and a high forecast of 42.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

2 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

18.00

Averages

28.40

High

42.00

Current: 0.000

Low

18.00

Averages

28.40

High

42.00

Evercore ISI

Outperform

downgrade

$22 -> $20

2026-01-05

New

Reason

Evercore ISI

Price Target

$22 -> $20

2026-01-05

New

downgrade

Outperform

Reason

Evercore ISI lowered the firm's price target on Novocure to $20 from $22 and keeps an Outperform rating on the shares. Recovering end markets and sector rotation have "set the stage for a 2026 Tools play," the analyst tells investors. In MedTech, the firm's survey work points to healthy procedure and CapEx trends into 2026 and early recovery signs in China support the group, but sector rotation and potential ACA and Medicare changes "have bears watching," the analyst added.

H.C. Wainwright

Buy

maintain

$38 -> $42

2025-10-30

Reason

H.C. Wainwright

Price Target

$38 -> $42

2025-10-30

maintain

Buy

Reason

H.C. Wainwright raised the firm's price target on Novocure to $42 from $38 and keeps a Buy rating on the shares following the Q3 report. The company's lung sales were inline with expectations while a Japan approval could provide a turnaround in 2026, the analyst tells investors in a research note.

JPMorgan

Jessica Fye

Neutral

downgrade

$25 -> $23

2025-10-27

Reason

JPMorgan

Jessica Fye

Price Target

$25 -> $23

2025-10-27

downgrade

Neutral

Reason

JPMorgan analyst Jessica Fye lowered the firm's price target on Novocure to $23 from $25 and keeps a Neutral rating on the shares. The firm updated the company's model to reflect increased long-term conservatism.

Wells Fargo

Larry Biegelsen

Overweight -> Equal Weight

downgrade

$40

2025-07-24

Reason

Wells Fargo

Larry Biegelsen

Price Target

$40

2025-07-24

downgrade

Overweight -> Equal Weight

Reason

Wells Fargo analyst Larry Biegelsen downgraded Novocure to Equal Weight from Overweight with a price target of $14.50, down from $40.

Wells Fargo

Overweight -> Equal Weight

downgrade

$40

2025-07-24

Reason

Wells Fargo

Price Target

$40

2025-07-24

downgrade

Overweight -> Equal Weight

Reason

Wells Fargo downgraded Novocure to Equal Weight from Overweight with a price target of $14.50, down from $40. The company reported \"disappointing\" Q2 results, including softer glioblastoma scripts outside the U.S. and a slow ramp in lung cancer, the analyst tells investors in a research note. Meanwhile, the pact from yhr PANOVA-3 and METIS studies are more than 12 months out, the firm adds. Wells is positive on Optune longer term but does not catalysts to drive share outperformance over the next year.

Ladenburg

Kevin Degeeter

initiated

$30

2025-07-08

Reason

Ladenburg

Kevin Degeeter

Price Target

$30

2025-07-08

initiated

Reason

Ladenburg analyst Kevin Degeeter initiated coverage of Novocure with a Buy rating and $30 price target.

Valuation Metrics

The current forward P/E ratio for Novocure Ltd (NVCR.O) is -8.92, compared to its 5-year average forward P/E of -8.38. For a more detailed relative valuation and DCF analysis to assess Novocure Ltd 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-8.38

Current PE

-8.92

Overvalued PE

426.50

Undervalued PE

-443.26

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-121.36

Current EV/EBITDA

-9.36

Overvalued EV/EBITDA

215.82

Undervalued EV/EBITDA

-458.55

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

11.41

Current PS

2.14

Overvalued PS

21.22

Undervalued PS

1.60

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders areBuying! The selling amount has increased 330.05% over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders areBuying! The selling amount has increased 330.05% over the last month.

Sold

Bought

NVCR News & Events

Events Timeline

No data

News

3.5

2025-12-31Businesswire

NovoCure Ltd (NVCR) Releases 2025 Product Pipeline Analysis Report

7.0

2025-12-31Barron's

Earnings Warning Season is Here: Strategies to Benefit from Others' Struggles.

9.5

2025-12-25Yahoo Finance

NovoCure Stock Down 56.6%, Yet Future Cash Flow Expected to Surge

People Also Watch

Frequently Asked Questions

What is Novocure Ltd (NVCR) stock price today?

The current price of NVCR is 14.35 USD — it has decreased -3.5 % in the last trading day.

What is Novocure Ltd (NVCR)'s business?

NovoCure Limited is a global oncology company with a proprietary platform technology called Tumor Treating Fields (TTFields), which are electric fields that exert physical forces to kill cancer cells via a variety of mechanisms. The Company's commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, non-small cell lung cancer, malignant pleural mesothelioma and pleural mesothelioma. Its Optune Gio is approved by the FDA under the Premarket Approval pathway for the treatment of adult patients with newly diagnosed glioblastoma together with temozolomide, a chemotherapy drug, and for adult patients with GBM following confirmed recurrence after chemotherapy as monotherapy treatment. Its Optune Lua is approved by the FDA under the PMA pathway for the treatment of adult patients with metastatic non-small cell lung cancer concurrent with PD-1/PD-L1 inhibitors or docetaxel following progression on or after a platinum-based regimen.

What is the price predicton of NVCR Stock?

What is Novocure Ltd (NVCR)'s revenue for the last quarter?

Novocure Ltd revenue for the last quarter amounts to 167.20M USD, increased 7.81 % YoY.

What is Novocure Ltd (NVCR)'s earnings per share (EPS) for the last quarter?

Novocure Ltd. EPS for the last quarter amounts to -0.33 USD, increased 17.86 % YoY.

What changes have occurred in the market's expectations for Novocure Ltd (NVCR)'s fundamentals?

How many employees does Novocure Ltd (NVCR). have?

Novocure Ltd (NVCR) has 1488 emplpoyees as of January 10 2026.

What is Novocure Ltd (NVCR) market cap?

Today NVCR has the market capitalization of 1.61B USD.